Better Therapeutics Inc
OTC:BTTX
Better Therapeutics Inc
Better Therapeutics, Inc. develops a software-based prescription digital therapeutics for treating diabetes, heart disease, and other cardiometabolic conditions. The company is headquartered in New York City, New York and currently employs 44 full-time employees. The company went IPO on 2021-01-08. The firm creates treatments to reverse the progression of disease, improve quality of life, and inform clinical decisions. The company builds prescription digital therapeutics that deliver a new kind of behavioral therapy and creating feedback mechanisms using remotely-monitored and patient-generated data. Its clinical development pipeline includes BT-001, BT-002, BT-003, BT-004 and BT-005. The company is evaluating BT-001 in a pivotal study as a prescribed treatment used under physician supervision for people with uncontrolled type 2 diabetes. The firm develops Nutritional Cognitive Behavioral Therapy (Nutritional CBT), which is a novel form of behavioral therapy under development for the treatment of patients with type 2 diabetes and other cardiometabolic diseases.
Better Therapeutics, Inc. develops a software-based prescription digital therapeutics for treating diabetes, heart disease, and other cardiometabolic conditions. The company is headquartered in New York City, New York and currently employs 44 full-time employees. The company went IPO on 2021-01-08. The firm creates treatments to reverse the progression of disease, improve quality of life, and inform clinical decisions. The company builds prescription digital therapeutics that deliver a new kind of behavioral therapy and creating feedback mechanisms using remotely-monitored and patient-generated data. Its clinical development pipeline includes BT-001, BT-002, BT-003, BT-004 and BT-005. The company is evaluating BT-001 in a pivotal study as a prescribed treatment used under physician supervision for people with uncontrolled type 2 diabetes. The firm develops Nutritional Cognitive Behavioral Therapy (Nutritional CBT), which is a novel form of behavioral therapy under development for the treatment of patients with type 2 diabetes and other cardiometabolic diseases.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
